Zacks Investment Research upgraded shares of Calyxt (NASDAQ:CLXT) from a sell rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. It researches and develops seeds and food ingredients for agricultural, feed, and food applications as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt, Inc. is based in New Brighton, United States. “

CLXT has been the topic of a number of other reports. Citigroup raised their price objective on shares of Calyxt from $13.00 to $16.00 and gave the company a neutral rating in a research note on Wednesday, February 27th. Goldman Sachs Group raised shares of Calyxt from a neutral rating to a buy rating and raised their price objective for the company from $9.25 to $18.00 in a research note on Sunday, December 16th. Jefferies Financial Group reaffirmed a buy rating and issued a $27.00 price objective on shares of Calyxt in a research note on Thursday, November 15th. Finally, National Securities assumed coverage on shares of Calyxt in a research note on Wednesday, March 6th. They issued a buy rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Calyxt has a consensus rating of Buy and a consensus price target of $21.80.

Shares of CLXT stock opened at $16.47 on Tuesday. Calyxt has a 52-week low of $8.83 and a 52-week high of $22.32. The company has a market capitalization of $553.73 million, a price-to-earnings ratio of -18.10 and a beta of 2.78. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.17.

Calyxt (NASDAQ:CLXT) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Calyxt had a negative net margin of 11,820.76% and a negative return on equity of 32.15%. As a group, equities analysts anticipate that Calyxt will post -1.05 earnings per share for the current year.

In other news, insider Daniel F. Voytas sold 8,170 shares of Calyxt stock in a transaction on Friday, February 1st. The shares were sold at an average price of $13.00, for a total transaction of $106,210.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel F. Voytas sold 4,083 shares of Calyxt stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $13.00, for a total transaction of $53,079.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,791 shares of company stock worth $261,718. Insiders own 2.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its position in shares of Calyxt by 14.8% during the fourth quarter. Bank of America Corp DE now owns 10,300 shares of the company’s stock worth $106,000 after purchasing an additional 1,330 shares in the last quarter. HRT Financial LLC bought a new position in shares of Calyxt during the fourth quarter worth $108,000. California Public Employees Retirement System boosted its position in shares of Calyxt by 17.0% during the fourth quarter. California Public Employees Retirement System now owns 11,700 shares of the company’s stock worth $121,000 after purchasing an additional 1,700 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Calyxt during the fourth quarter worth $139,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Calyxt by 33.1% during the fourth quarter. Bank of New York Mellon Corp now owns 21,447 shares of the company’s stock worth $222,000 after purchasing an additional 5,336 shares in the last quarter. 27.13% of the stock is currently owned by institutional investors.

Calyxt Company Profile

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.

See Also: Strike Price

Get a free copy of the Zacks research report on Calyxt (CLXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.